Herbert Irving Comprehensive Cancer Center
37
3
4
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 37 trials
100.0%
+13.5% vs industry average
5%
2 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (37)
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Role: collaborator
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
Role: collaborator
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Role: collaborator
Testing Gene PilotLX With Latinx Cancer Patients
Role: collaborator
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Role: lead
Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
Role: lead
Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer
Role: lead
CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Role: lead
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
Role: lead
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
Role: lead
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
Role: lead
Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
Role: lead
Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma
Role: lead
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Role: lead
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
Role: lead
Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
Role: lead
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
Role: lead
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
Role: lead
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
Role: lead
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
Role: lead